EVH logo

Evolent Health Inc Class A (EVH)

$4.22

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EVH

Market cap

$474670103

EPS

-4.68

P/E ratio

--

Price to sales

0.23

Dividend yield

--

Beta

0.841157

Price on EVH

Previous close

$4.38

Today's open

$4.38

Day's range

$4.13 - $4.44

52 week range

$2.10 - $12.07

Profile about EVH

CEO

Seth Blackley

Employees

4500

Headquarters

Arlington, VA

Exchange

New York Stock Exchange

Shares outstanding

112481067

Issue type

Common Stock

EVH industries and sectors

Healthcare

Healthcare Providers & Services

News on EVH

Agentic AI Powers U.S. Healthcare Stocks

Healthcare payrolls keep climbing, and hospital systems, payers, and clinics are now openly treating agentic AI as the cheapest unit of labor on the market.

news source

24/7 Wall Street • May 18, 2026

news preview

Evolent Health Q1 Earnings Call Highlights

Evolent Health NYSE: EVH reported first-quarter 2026 results that management said were in line with expectations, while reiterating its full-year outlook and highlighting new contract wins, early progress on major client launches and continued investment in automation.

news source

MarketBeat • May 10, 2026

news preview

Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 8, 2026

news preview

Evolent Announces First Quarter 2026 Results

WASHINGTON, May 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year.

news source

PRNewsWire • May 7, 2026

news preview

Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates

Evolent Health (EVH) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.06 per share a year ago.

news source

Zacks Investment Research • May 7, 2026

news preview

Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • May 7, 2026

news preview

Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, with a conference call to follow at 8 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

news source

PRNewsWire • Apr 7, 2026

news preview

Evolent announces appointment of Archie Mayani as chief product officer

Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).

news source

PRNewsWire • Mar 19, 2026

news preview

Evolent to Participate in Upcoming Investor Conferences

WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences.  A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website.

news source

PRNewsWire • Feb 26, 2026

news preview

Evolent Health: Cheap, Levered, But Ready To Rebound

Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via AI automation and workforce efficiencies delivering $20M+ in annualized savings.

news source

Seeking Alpha • Feb 26, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Evolent Health Inc Class A

Open an M1 investment account to buy and sell Evolent Health Inc Class A commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EVH on M1